Enterprise Value

61.52M

Cash

189.6M

Avg Qtr Burn

-18.26M

Short % of Float

10.77%

Insider Ownership

14.81%

Institutional Own.

74.00%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1b

Data readout

ORIC-114 (EGFR/HER2 Inhibitor) Details
Solid tumor/s, Advanced malignancies

Phase 1b

Data readout

Phase 1b

Data readout

Failed

Discontinued

Failed

Discontinued